Natriumoxybaat Accord (Sodium Oxybate)

Sodium Oxybate, the active ingredient in Natriumoxybaat Accord, is a Gamma‑hydroxybutyrate (GHB) class presented as an oral formulation for oral use. It is prescribed to treat narcolepsy with cataplexy, helping to consolidate nighttime sleep and reduce cataplexy episodes in affected patients, thereby improving daytime alertness significantly.

GNH USA supplies Natriumoxybaat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution.

Sodium Oxybate acts on the central nervous system to address symptoms of the narcolepsy disorder spectrum.

- Narcolepsy with cataplexy: reduces the frequency and severity of cataplexy episodes. - Excessive daytime sleepiness associated with narcolepsy: improves daytime alertness by enhancing nocturnal sleep quality. - Overall narcolepsy symptom control: contributes to better sleep consolidation and reduced sleep attacks.

Sodium oxybate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: sensation of lightheadedness. - Nasal congestion: blockage or runny nose.

Serious or Rare Side Effects: - Respiratory depression: reduced breathing effort, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Abuse potential: risk of dependence due to GHB class properties.

When prescribing sodium oxybate, clinicians should observe several safety considerations to minimize risk. - Contraindication: avoid use in patients with known hypersensitivity to sodium oxybate. - Respiratory disorders: monitor closely in individuals with sleep‑disordered breathing or COPD. - Concomitant CNS depressants: limit use with alcohol or benzodiazepines due to additive sedation. - Pregnancy and lactation: assess risk–benefit; limited data available. - Driving and operating machinery: advise patients that dizziness may impair performance. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Sodium oxybate can interact with other medicines, altering its effects or safety profile.

Major Interactions (Avoid): - Alcohol: combined use can cause profound respiratory depression and sedation. - Opioids: additive CNS depression may lead to life‑threatening outcomes.

Moderate Interactions (Monitor Closely): - Benzodiazepines: may enhance sedative effects, requiring dose adjustments. - Antidepressants (e.g., SSRIs): potential for increased serotonergic activity. - Antihistamines: may intensify drowsiness. - Sodium‑containing medications: monitor total sodium load to avoid fluid retention.